Research Reports | Market Assessment
March 2022

Renal Anemia – Current Treatment – Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis

Renal anemia is a common complication of chronic kidney disease. The primary goal of treatment of renal anemia is to increase and maintain hemoglobin levels and reduce the risk of complications of chronic hypoxia, higher mortality rates, and cardiovascular disease. Renal anemia nondialysis patients are initially treated with oral iron, followed by IV iron; ESAs are prescribed as third-line therapy. Dialysis patients usually receive IV iron therapy followed by ESAs. Several ESAs and iron supplements are available and have had varying degrees of commercial success. Key approved agents include Amgen’s Epogen, Janssen’s Procrit, Pfizer’s Retacrit, Amgen’s Aranesp, Roche / Chugai’s Mircera, and Keryx’s Auryxia. This report provides important insights into how these agents are used to manage renal anemia and how practice is evolving.

Table of contents

  • Renal Anemia - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis
    • Treatment Algorithms CDA Renal Anemia US March 2022
    • Treatment Algorithms CDA Renal Anemia 2022 Dashboard
Tej Pal, M.Pharm.
Tej Pal, M.Pharm.

Tej Pal, M.Pharm., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports